Primary hyperparathyroidism and incidental multifocal metastatic papillary thyroid carcinoma in a man

Hiperparatiroidismo primário e carcinoma papilífero metastático, multifocal e incidental da tiroide em paciente do sexo masculino

Stergios A. Polyzos¹, Athanasios D. Anastasilakis², Ioannis P. Iakovou³, Valassia Partsalidou⁴

SUMMARY

Co-existence of primary hyperparathyroidism (PHPT) and non-medullary thyroid carcinoma has been previously reported in sporadic case reports and some surgical series, but the majority of cases concerned women with occult papillary carcinomas without cervical lymph node involvement. We present a 71-year man with PHPT and multinodular goiter who was subjected to surgery for single parathyroid adenoma and was found to have synchronous multifocal papillary thyroid carcinoma (PTC) with cervical lymph node involvement. Review of the literature retrieved only a few similar cases. Ultrasonography of both thyroid and parathyroid glands might be considered in patients with hyperparathyroidism. Given that there are no specific guidelines for the management of patients with synchronous PHPT and PTC, they should be managed like the cases of single PTC. Arq Bras Endocrinol Metab. 2010;54(6):578-82

SUMÁRIO

A coexistência de hiperparatiroidismo primário (HPTP) e de carcinoma da tiroide não medular foi descrita anteriormente em relatos de caso esporádicos e em algumas séries cirúrgicas. Entretanto, a maioria dos casos se referiu a mulheres com carcinoma papilífero oculto sem comprometimento de linfonodos cervicais. Apresentamos um paciente de 71 anos de idade do sexo masculino com HPTP e bócio multinodular que foi submetido a uma cirurgia para adenoma solitário da paratiroide e foi encontrado carcinoma papilífero da tiroide (PTC) multifocal com comprometimento de linfonodos cervicais. Uma revisão da literatura resultou em apenas alguns casos similares. A realização de uma ultrassonografia das glândulas tiroide e paratiroides pode ser considerada em pacientes com hiperparatiroidismo. Como não existe diretriz específica para o tratamento de pacientes com concomitância de HPTP e PTC, eles devem ser tratados como um caso isolado de PTC. Arq Bras Endocrinol Metab. 2010;54(6):578-82

INTRODUCTION

Primary hyperparathyroidism (PHPT) is the third most common endocrine disorder and a single gland adenoma is accounting for 75%-85% of the cases (1). The incidence of PHPT is currently 27-30 per 100,000 person-years; it is twice as high in women and increases with age. Asymptomatic disease is common. The treatment of choice for PHPT is surgical removal of the hyperfunctioning tissue. Experienced surgeons are estimated to identify an affected gland in 95% of cases (1). However, there is still controversy about the first option therapy for PHPT, especially in asymptomatic patients older than 50 years (1,2).

Papillary thyroid carcinoma (PTC) is the most common malignant tumor of the thyroid. It usually presents as a solitary or dominant nodule, but multifocality is not uncommon (3). The incidence of PTC (currently 7.7 per 100,000 person-years in the United States) is higher in women and is rising, predominantly due to the increased detection of occult papillary carcinomas, which have negligible impact on overall mortality (4,5). Total thyroidectomy, which may be followed by ablation with
radioactive iodine, is the recommended management for PTC and the prognosis is usually favorable (6).

Co-existence of PHPT and non-medullary thyroid carcinoma (NMTC) has been previously reported in case reports and some surgical series. In large series, NMTC was reported to be between 2.1% and 4.3% in patients subjected to surgery for PHPT (7-13). The majority of the cases were women with unifocal occult PTC without cervical lymph node involvement; many of them were associated with previous head and neck irradiation.

We present hereby a man with PHPT due to a single parathyroid adenoma and multinodular goiter, who was subjected to surgery and was found to have synchronous bilateral multifocal PTC with cervical lymph node involvement.

CASE REPORT

A 71-year-old asymptomatic man presented to our clinic (October 2008) for mild biochemical hypercalcemia (serum calcium 10.8 mg/dL, reference range 8.1-10.4 mg/dL) incidentally found on routine check-up. He had had essential hypertension since 1992, hyperlipidemia since 2002 and atrial fibrillation since 2005. At presentation, he was receiving amlodipine 5 mg, celiprolol hydrochloride 200 mg and atorvastatin 10 mg once daily. The patient reported no history of head or neck irradiation or a neck mass. Clinical examination was unremarkable. Blood tests revealed mildly elevated serum total calcium (10.6 mg/dL), low-normal phosphate 2.5 mg/dL (reference range 2.5-4.5 mg/dL) and increased serum intact parathyroid hormone (PTH) (202 pg/mL, reference range 7-53 pg/mL), findings suggestive for PHPT. The patient had normal 24-hour urinary calcium excretion (251 mg/day, reference range 100-300 mg/day) and 24-hour urinary total metanephrines (55 μg/day, normal < 600 μg/day). Serum thyroid-stimulating hormone (TSH), free thyroxine (FT4) and calcitonin were normal (2.7 IU/L, 1.4 ng/dL and 1 pg/mL, respectively; reference ranges 0.4-4.0 IU/L, 0.8-1.9 ng/dL and 0-10 pg/mL, respectively). Serum kidney and liver function tests were normal, as well as creatinine clearance.

Two phase Technetium (99mTc)-Sestamibi scintigraphy revealed an area of increased radioactivity at the inferior pole of the left thyroid lobe, which was suggestive of a parathyroid adenoma (Figure 1A). Ultrasonography of the neck revealed a potential 1-cm parathyroid adenoma at the inferior pole of the left thyroid lobe and a multinodular goiter. Three thyroid nodules had maximum diameter over 1 cm. Two of them were hypoechogenic. The dominant nodule was in the right thyroid lobe; it had microcalcifications and its maximum diameter was 1.5 cm. Nodules were clinically impalpable, possibly because the patient’s neck was short and thick.

The patient was subjected to uncomplicated parathyroidectomy of his left inferior parathyroid gland and synchronous total thyroidectomy. No suspicious cervical lymph nodes were found during intraoperative exploration. PTH was normalized postoperatively and remains normal 15 months later. However, serum calcium fell below normal (7.7 mg/dL) at the third postoperative day and the patient was placed on tablets of calcium carbonate (1,500 mg) and capsules of alphacalcidol (1 μg), which were received orally every day; normocalcemia was restored soon after treatment. Calcium carbonate was discontinued two months later, but repeated efforts to discontinue alphacalcidol resulted in mild hypocalcemia and the patient continues receiving it to sustain serum calcium at low normal levels.

Pathology examination revealed a parathyroid adenoma (left) of maximum diameter 1.5 cm (Figure 2a) and a small normal parathyroid gland inside the right lobe of the thyroid (Figure 2b). Interestingly, there were three small lymph nodes within the fatty tissue around the parathyroid adenoma, one of which was incidentally found to contain metastatic PTC (Figure 2c). Furthermore, bilateral, multifocal PTC of both classical and follicular variants was found with focal infiltration of fatty tissue around the right lobe of the thyroid.

Three months later (March 2009) the patient received radioiodine ablation dose of 100 mCi 131I followed by suppressive treatment with thyroxine (175 μg/day). Eight months later, in November 2009, a whole
Primary hyperparathyroidism and Papillary Ca


dISCUSSION

We presented the case of a man with PHPT due to single parathyroid adenoma, who was incidentally found to have concomitant multifocal metastatic PTC. What makes this case exceptional is the extent of thyroid disease, because unifocal occult microcarcinomas were described in most of the previously reported cases.

Based on the incidences of PHPT and PTC (1,4,5), the incidence of co-existence of PHPT and PTC could be roughly estimated to be 0.0023 per 100,000 person-years, if their co-existence is simply attributed to chance. In large surgical series (7-13), NMTC has been reported to be between 2.1% and 4.3% in patients subjected to surgery for PHPT. Even higher frequency has been reported in smaller surgical series (14,15). However, given that the variation in frequency depends on the method of examination, patient selection, sample size and surgical procedure, potential selection bias is usually greater by decreasing the sample size. The true incidence of PTC in patients with PHPT is unknown, because: 1) not all patients with PHPT are subjected to surgery; 2) neck exploration is impossible during minimally invasive parathyroidectomy, which becomes more and more popular for patients with PHPT (14).

The association of PHPT and NMTC has elicited speculations for a causative relationship, but the pathogenesis for this concurrence, if any, remains largely unknown. Some authors suggest that it is simple coinci-
cence with no causal relationship (7,8). It may result from the vicinity of thyroid and parathyroid glands, interpreted in more neck imaging studies due to PHPT and/or exploration of the thyroid during parathyroidectomy. Furthermore, both diseases are predominantly diagnosed in middle-aged women. The high prevalence of occult thyroid carcinoma (5.3%-6.2%) found in large autopsy studies (16,17) is similar with that found in the above mentioned large surgical series (7-15), which further supports simple coincidence. Finally, PHPT and PTC have different embryologic cell origin (18). On the other hand, other authors suggest previous head and neck irradiation be a common pathogenetic factor for the development of both PHPT and NMTC (7,11), but controversy exists (19). The goitrogenic and carcinogenic effects of calcium and the excessive production of calcitonin in response to hypercalcemia have also been proposed as potential pathogenetic mechanisms (19), but solid evidence is currently lacking; both these hypotheses consider a primary parathyroid abnormality with a secondary effect on the thyroid. A possible common responsible gene and/or growth factors may also play a role (10,14,19), but solid evidence is also lacking.

By reviewing, the above surgical series (7-15) and sporadic case reports (18,20-22), it is observed that: 1) the majority of patients with concurrent PHPT and NMTC are women, possibly due to the increased incidence of both PHPT and PTC in women; 2) most cases are about the classical variant of occult PTC (< 1 cm), the clinical significance of which is questionable (4,5); 3) bilateral insult, multifocality and lymph node involvement are only rarely reported. To our knowledge, similar cases that have been reported in men are a case of multifocal PTC with cervical lymph node involvement (23) and a case of bilateral multifocal PTC (10). There are some relative data in two of the above mentions large surgical series (7,9), but the gender of patients was not specified in patients with extensive PTC.

There are not specific guidelines for the management of patients with concurrent PHPT and PTC; PTC in these patients is currently managed like cases of single PTC, according to recent guidelines (6). If thyroid nodular disease coexists in patients with PHPT apart from MEN syndromes, NMTC should also be excluded. Ultrasonography of the thyroid might be considered in patients with PHPT simultaneously with parathyroid ultrasonography. Preoperative thyroid fine-needle biopsy and intraoperative exploration should also be considered, before thyroidectomy is performed together with parathyroidectomy, in order to avoid unnecessary thyroidectomy or determine the extent and radicalness of the surgery. Especially in men, a more aggressive management should be considered, since they may carry a higher risk of malignancy, as in the cases of single thyroid nodular disease (24).

In conclusion, the cases with PHPT and incidental bilateral, multifocal, metastatic PTC are rare, especially in men. Ultrasonography of both thyroid and parathyroid glands might be considered in patients with PHPT. In case of concurrent PHPT and PTC, the patient should be managed like the cases of single PTC, according to recent guidelines (6).

Disclosure: no potential conflict of interest relevant to this article was reported.

REFERENCES

Primary hyperparathyroidism and Papillary Ca


